<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="15095">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02910362</url>
  </required_header>
  <id_info>
    <org_study_id>CP-02</org_study_id>
    <nct_id>NCT02910362</nct_id>
  </id_info>
  <brief_title>Intra-surgical Evaluation of CATS Tonometer Prism and Abbott Medical Optics Versus Alcon Phacoemulsification Machines</brief_title>
  <official_title>INTRA-SURGICAL EVALUATION OF CATS TONOMETER PRISM AND ABBOTT MEDICAL OPTICS VERSUS ALCON PHACOEMULSIFICATION MACHINES</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intuor Technologies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott Medical Optics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Intuor Technologies, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will measure the dynamic real-time IOP in the anterior chamber during standard
      phacoemulsification surgery.

      What is known:

        -  Fluidics control is determined to be one of the primary drivers of physician decision
           making in choosing phacoemulsification equipment.

        -  Active pressure system fluidic control has a perceived and possibly real (based upon
           recent literature) improvement in intra-cameral IOP stability and reduced pressure
           fluctuations.

        -  Improved fluidics can allow for reduced dynamic IOP fluctuations, in-the-bag positioned
           phaco tip, and intra-cameral fluid flow all of which will likely improve corneal health
           post-operatively.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine statistical significance in IOP stability between Abbott and Alcon phacoemulsification equipment.</measure>
    <time_frame>intraoperative</time_frame>
    <description>Mean IOP, variance, and RMS statistical significance between cohorts with 95% CI, 3 way ANOVA and student t-test between machines. Binary logistical regression between Abbott and Alcon phacoemulsification equipment examining expected independent variables and possible confounding factors.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine statistical significance in inflammation and corneal edema between Abbott and Alcon phacoemulsification equipment.</measure>
    <time_frame>intraoperative</time_frame>
    <description>Mean IOP, variance, and RMS statistical significance between cohorts with 95% CI, 3 way ANOVA and student t-test between machines. Binary logistical regression between Abbott and Alcon phacoemulsification equipment examining expected independent variables and possible confounding factors.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine statistical significance in endothelial cell loss between Abbott and Alcon phacoemulsification equipment.</measure>
    <time_frame>intraoperative</time_frame>
    <description>Mean IOP, variance, and RMS statistical significance between cohorts with 95% CI, 3 way ANOVA and student t-test between machines. Binary logistical regression between Abbott and Alcon phacoemulsification equipment examining expected independent variables and possible confounding factors.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Cataract Surgery</condition>
  <arm_group>
    <arm_group_label>Alcon phacoemulsification equipment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cataract surgery performed with the Alcon phacoemulsification equipment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AMO phacoemulsification equipment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>cataract surgery with the AMO phacoemulsification equipment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Alcon phacoemulsification equipment</intervention_name>
    <description>cataract surgery with Alcon phacoemulsification equipment.</description>
    <arm_group_label>Alcon phacoemulsification equipment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AMO phacoemulsification equipment</intervention_name>
    <description>cataract surgery with AMO phacoemulsification equipment.</description>
    <arm_group_label>AMO phacoemulsification equipment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  • Age 18 or greater

               -  Bilateral cataracts for which phacoemulsification extraction and posterior IOL
                  implantation has been planned for both eyes

               -  Subjects able to give informed consent

               -  Nuclear Sclerotic cataract graded 2+ or 3+

               -  Naturally dilated pupil size (in dim light) &gt; 4.0 mm (with no dilation
                  medications) for both eyes

               -  Preoperative corneal astigmatism of 2.5 D or less

               -  Ages between 55 and 80

               -  Availability, willingness, and sufficient cognitive awareness to comply with
                  examination procedures

        Exclusion Criteria:

          -  • Uncontrolled systemic disease that in the opinion of the Investigator would put the
             subject's heath at risk

               -  Intraoperative complications

               -  Subjects with only one functional eye

               -  Those with one eye having poor or eccentric fixation

               -  Mild or severe cataracts, predominantly posterior subcapsular cataracts

               -  High corneal astigmatism (i.e. those eyes displaying an oval contact image)

               -  Those with corneal scarring or who have had corneal surgery including corneal
                  laser surgery

               -  Microphthalmos

               -  Buphthalmos

               -  Severe Dry eyes

               -  Blepharospasm

               -  Nystagmus

               -  Keratoconus

               -  Any other corneal or conjunctival pathology or infection.

               -  Central corneal thickness greater than 0,600 mm or less than 0,500 mm (2
                  standard deviations about the human mean)

               -  Acute or chronic disease or illness that would increase risk or confound study
                  results (e.g. diabetes mellitus, immunocompromised, etc.)

               -  Uncontrolled systemic or ocular disease

               -  History of ocular trauma or prior ocular surgery

               -  Fuchs Dystrophy

               -  Subjects who may be expected to require retinal laser treatment or other
                  surgical intervention, including LRI's

               -  Capsule or zonular abnormalities that may affect postoperative centration or
                  tilt of the lens (e.g. pseudoexfoliation syndrome)

               -  Pupil abnormalities (non-reactive, tonic pupils, abnormally shaped pupils, or
                  pupils that do not dilate at least 4.0 mm under mesopic/scotopic conditions)

               -  Contact lens usage within 6 months for PMMA contacts lenses, 1 month for gas
                  permeable lenses or 1 week for extended-wear and daily-wear soft contact lens
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nannon Roosa</last_name>
    <phone>520-370-4113</phone>
    <email>nroosa@intuortec.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Omid Khodai, OD</last_name>
    <phone>9497354727</phone>
    <email>omid@drkhodai.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Arizona Eye Consultants</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sean McCafferty, MD</last_name>
      <phone>520-327-3487</phone>
      <email>sjmccafferty66@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 28, 2016</lastchanged_date>
  <firstreceived_date>September 13, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dipivefrin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
